Hybrid prehabilitation before lung surgery

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional comparison tests a 15-session hybrid prehabilitation program (home plus center sessions) against a standard 15-session center-based program for patients awaiting lung resection for non-small cell lung cancer. The primary outcome is change in aerobic capacity measured as peak oxygen uptake before and after the program. Eligible participants are adults referred for prehabilitation with peak VO2 below 20 ml/kg/min and with surgery scheduled at least four weeks away or not yet dated. The protocol excludes patients requiring oxygen during exercise, those with cardiac contraindications, or those undergoing neoadjuvant chemoradiotherapy.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age \> 18 years
* Patient scheduled to undergo lung resection for the treatment of diagnosed or suspected bronchial cancer
* Referred for prehabilitation before lung resection surgery
* Patient living at home with another adult present during exercise sessions
* Surgery date not established at the time of inclusion in the program, or at least 4 weeks away
* Peak oxygen uptake below 20 ml/kg/min
* Affiliated with a health insurance system
* Able to read and understand the information letter and sign the consent form

Non-Inclusion Criteria\*:

* Oxygen therapy during exercise
* Cardiological contraindication to exercise training
* Refusal to participate in a center-based prehabilitation training program
* Orthopedic, neurological, vascular, or neuromuscular conditions limiting exercise training on a cycle ergometer
* Patient under guardianship or curatorship
* Pregnant or breastfeeding women

Exclusion Criteria:

-Withdrawal of consent

\*The eligibility criteria were revised in May 2026 following approval of a protocol amendment by the French Ethics Committee (CPP Île-de-France IV). The former non-inclusion criterion of patients receiving concomitant neoadjuvant chemoradiotherapy was removed to better reflect the study population to current clinical practice, as neoadjuvant treatments are increasingly integrated into the care pathway of patients undergoing thoracic surgery for non-small cell lung cancer and referred for pulmonary prehabilitation. The previous restriction had been too limiting and had slowed recruitment. This amendment was proposed to improve the feasibility of recruitment and to increase the representativeness of the study population, while ensuring the safety of the participants as no additional safety concerns were identified and all other exclusion criteria related to safety were unchanged.

Where it's running

• Association ADIR
  Rouen, France Recruiting

Study contacts

• Principal investigator: Tristan Bonnevie, PhD — Association ADIR
• Study coordinator: Tristan Bonnevie, PhD
• Email: t.bonnevie@adir-hautenormandie.com
• Phone: 0235592970

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Patient-specific MRD liquid biopsy for resected NSCLC

  This study tests a personalized MRD blood and bronchial washing test after surgery to see if it can signal recurrence earlier in people with resected NSCLC.

  Recruiting Yonsei University · Yongin-si, Gyeonggi-do and 2 other locations · NCT07921888

• Osimertinib Plus SRS/SRT for EGFR-Mutant NSCLC with Symptomatic Brain Metastases

  This study tests whether adding targeted brain radiotherapy to osimertinib helps control brain metastases in adults with EGFR-mutant NSCLC and neurological symptoms.

  Recruiting Phase 2 Cho Ray Hospital · Ho Chi Minh City · NCT07911449

• Dato-DXd in solid tumors (Urothelial Cancer and KRAS-mutant NSCLC) in two sub-studies

  This study tests Datopotamab Deruxtecan (Dato-DXd) alone or with other cancer drugs in people with urothelial cancer or KRAS-mutant non-small cell lung cancer.

  Recruiting Phase 1/2 Daiichi Sankyo · Taichung · NCT07890714

• SI-B036 safety test in advanced and metastatic solid tumors

  This early-phase study checks whether SI-B036 is safe and tolerable in adults with advanced or metastatic solid cancers who have had prior therapy.

  Recruiting at 4 sites Phase 1 SystImmune Inc. · New Haven, Connecticut and 6 other locations · NCT07857616

• Postoperative EGFR-TKI Therapy for EGFR-mutant NSCLC Following Surgery

  This registry tests whether giving an EGFR-TKI after surgery helps adults with EGFR-mutant, high-risk early-stage NSCLC.

  Recruiting Tongji Hospital · Wuhan, Hubei · NCT07837739

• HS-20093 with Adebrelimab vs HS-20093 alone in advanced non-squamous NSCLC

  This study tests whether adding adebrelimab to HS-20093 helps patients with advanced non-squamous NSCLC who have already had treatment.

  Recruiting Phase 2 Hansoh BioMedical R&D Company · Wuhan, Hubei · NCT07824882

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.